LKA651
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $6,230 | 9 | 0 |
| 2019 | $4,410 | 7 | 0 |
| 2018 | $41,384 | 8 | 0 |
| 2017 | $187,935 | 8 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $239,960 | 32 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A RANDOMIZED SINGLE MASKED SHAM CONTROL SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMIC ACTIVITY OF INTRAVITREAL LKA651 IN PATIENTS WITH MACULAR EDEMA FROM DIABETIC MACULAR EDEMA DME NEOVASCULAR AGE RELATED MACULAR DEGENERATION AMD OR RETINAL VEIN OCCLUSIONS RVO | Novartis Pharmaceuticals Corporation | $229,320 | 0 |
| A RANDOMIZED, ACTIVE-CONTROLLED, SUBJECT AND INVESTIGATOR-MASKED, MULTIPLE DOSE PROOF-OF-CONCEPT STUDY OF INTRAVITREAL LKA651 IN PATIENTS WITH DIABETIC MACULAR EDEMA | Novartis Pharmaceuticals Corporation | $10,640 | 0 |
Top Doctors Receiving Payments for LKA651
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Winter Haven, FL | $239,960 | 32 |
Manufacturing Companies
- Novartis Pharmaceuticals Corporation $239,960
Product Information
- Type Biological
- Total Payments $239,960
- Total Doctors 0
- Transactions 32
About LKA651
LKA651 is a biological associated with $239,960 in payments to 0 healthcare providers, recorded across 32 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $6,230 was paid across 9 transactions to 0 doctors.
The most common payment nature for LKA651 is "Unspecified" ($239,960, 100.0% of total).
LKA651 is associated with 2 research studies, including "A RANDOMIZED SINGLE MASKED SHAM CONTROL SINGLE ASCENDING DOSE STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND PHARMACODYNAMIC ACTIVITY OF INTRAVITREAL LKA651 IN PATIENTS WITH MACULAR EDEMA FROM DIABETIC MACULAR EDEMA DME NEOVASCULAR AGE RELATED MACULAR DEGENERATION AMD OR RETINAL VEIN OCCLUSIONS RVO" ($229,320).